Please login to the form below

LAMA

This page shows the latest LAMA news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol, LAMA

Latest news

EMA approves GSK’s triple COPD therapy

The same indication was approved by the FDA in September, and makes Trelegy the first drug on the market to combine an ICS, LABA and long-acting muscarinic receptor antagonist (LAMA)
With US approval, GSK now needs rapid uptake for COPD triple

The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product
GSK closes in on EU approval for triple COPD therapy

The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... GSK thinks it has a decent head
GSK preps COPD filing for asthma pioneer Nucala

agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium – and shingles vaccine Shingrix which is up for an FDA advisory committee meeting later today.
Chiesi Group's Trimbow wins European licence

The treatment comprises an inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in one inhaler and is the such triple combination COPD therapy to be ... Administered twice daily at a fixed dose,

More from news
Approximately 3 fully matching, plus 48 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.
Pharma deals in February 2015

The co-development and marketing deal with Theravance involves TD-4208 a novel, phase 3 ready, once-daily, nebulised, long-acting muscarinic antagonist (LAMA) under development to treat COPD and other
Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

Currently in phase III clinical development for COPD, this combination of a long acting beta-2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Business Unit Head, Medical Communications, London: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Client Services Director – Healthcare Advertising - London: Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Delivery Manager/ Head of Delivery – Executive Search: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Manager: £40, 000 - £45, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....